

July 23, 2026

BSE LimitedPhiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001**Scrip Code: 539871****National Stock Exchange of India Limited**Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051**Symbol: THYROCARE****Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/ Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you as under:

Nuclear Healthcare Limited ("Wholly Owned Subsidiary of the Company" / "NHL") is engaged in the business of advanced cancer diagnostics and nuclear medicine. NHL operates PET-CT and CT imaging centres, provides nuclear medicine diagnostic services and manufactures radiopharmaceuticals through its medical cyclotron facilities, supporting the early detection, diagnosis, staging and monitoring of cancer and other complex diseases.

The Board of Directors of the Company, at its meeting held today, i.e., Thursday, July 23, 2026 discussed and in-principle approved the evaluation of a proposed demerger of NHL's radiology business undertaking to outside the group, by way of a scheme of arrangement or slump sale or business transfer or any other appropriate structure or mode, as may be evaluated, subject to requisite regulatory and statutory approvals ("**Proposed Restructuring**").

The Proposed Restructuring is at an in-principle evaluation stage. The detailed terms of the proposed transaction shall be placed before the Board of Directors of NHL at the appropriate time, following which necessary disclosures and filings shall be made with the Stock Exchanges and other regulatory/statutory authorities, as applicable.

The Company will ensure compliance with all applicable regulatory requirements, including under the Companies Act, 2013 and the Listing Regulations, at each stage of the Proposed Restructuring, including intimation to the Stock Exchanges.

The above disclosures are also being made available on the website of the Company at <https://investor.thyrocare.com>.

The Board Meeting commenced at 2:45 P.M. and concluded at 03:35 P.M.

This is for your information and records.

Thanking you,
Yours faithfully,

For Thyrocare Technologies Limited**Brijesh Kumar**
Company Secretary & Compliance Officer

Thyrocare Technologies Limited